Bioarctic

With patients in mind, we are committed to our vision: A world where scince defeats severe brain diseases. BioArctic AB (publ) is an innovative Swedish biopharma company focusing on research and develop into neurodegenerative diseases, such as Alzheimer's disease, Parkinson's disease and ALS. With world-leading science and strong collaborations, we create, develop, and provide innovative treatments for patients with severe brain diseases. BioArctic has also developed the BrainTransporter™ technology, which has the potential to actively transport antibodies and other biological molecules across the blood-brain barrier to enhance distribution in the brain and drug efficacy. Collaborations are of great importance to the company and partnering with global pharma companies is a key element of our strategy. Our project portfolio is broad and well-diversified, with the potential to significantly improve the health of patients. The company was founded in 2003 based on innovative research at Uppsala University.